The study reports that in NSCLC cell lines, afatinib decrease the phosphorylation of ELK1 and this led to a reduction in Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) gene transcription [49]. This evidence concerns the gene ELK1 and non-small cell lung carcinoma.